GH Research PLC (GHRS) Stock Price & Analysis
GH Research PLC (GHRS) closed at USD 20.71 on Wednesday, October 28, 2026, up 3.45% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 20.02; the Oct 28, 2026 session ranged USD 19.52–20.79 on volume of 198,718 shares. Market capitalization is $1.42B, with a 52-week range of USD 12.04–31.44 (NGM). Source: Nexqual, retrieved October 29, 2026 at 12:56 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GHRS.md
Key facts (GHRS)
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 42.89 (range 38–65).
- Total return with dividends: 1Y +50.4% vs S&P 500 +13.6%; 5Y -18.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.3, revenue estimate $0K.
Analysts (GHRS)
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 42.89 (low 38, high 65).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Guggenheim | Target raised | Buy | $34 → $40 |
| 2026-08-07 | Cantor Fitzgerald | Target raised | Overweight | $35 → $40 |
| 2026-08-06 | Needham | Target raised | Buy | $32 → $39 |
| 2026-07-27 | Wells Fargo | Initiated | Overweight | $44 |
Total return (dividends reinvested) (GHRS)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +50.4% | -18.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +50.6% | -3.9% |
| Volatility (annualized) | 69.9% | 69.2% |
| Max drawdown | -41.0% (Aug 2026→Oct 2026) | -79.2% (Nov 2021→Jan 2024) |
GHRS earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.23 | −$0.30 | Beat +23.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.31 | −$0.26 | Miss −19.2% | — |
| — | Quarter ended Dec 31, 2025 | −$0.22 | −$0.27 | Beat +18.5% | — |
| — | Quarter ended Sep 30, 2025 | −$0.23 | −$0.23 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
GHRS recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 9, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 9, 2026 |
| Sep 11, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 11, 2026 |
| Aug 14, 2026 | Schedule 13G/A | RA Capital Management, L.P., Peter Kolchinsky: 7.1% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Lynx1 Capital Management LP, Weston Nichols: 19.3% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | 6-K | Current report (foreign issuer) · period ended Jun 30, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
GHRS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.30 | $-0.36 | +$0.06 | $0 | 9 |
| Next quarter (ends Dec 2026) | $-0.35 | $-0.42 | +$0.07 | $0 | 9 |
| Current fiscal year (ends Dec 2026) | $-1.17 | $-1.40 | +$0.23 | $0 | 9 |
| Next fiscal year (ends Dec 2027) | $-1.85 | $-2.00 | +$0.15 | $0 | 9 |
GHRS options: expected move
Options price a move of about ±24.4% (±$5.05) by Nov 20, 2026, which includes earnings on Nov 5, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 123.8% | ±24.4% |
| Dec 18, 2026 | 50 | 90.5% | ±26.4% |
| Jan 15, 2027 | 78 | 77.8% | ±26.3% |
| Apr 16, 2027 | 169 | 65.6% | ±34.5% |
30-day implied volatility 78.2% vs 56.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 12:56 UTC)
| Price | USD 20.71 |
|---|---|
| Change | ▲ 3.45% (up) |
| Previous Close | USD 20.02 |
| Open | USD 19.91 |
| Day Range | USD 19.52 – 20.79 |
| 52-Week Range | USD 12.04 – 31.44 |
| Volume | 198,718 shares |
| Market Cap | $1.42B |
| Exchange | NGM |
Technical Analysis (GHRS)
Nexqual's technical model rates GHRS "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 12:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.35 (neutral) |
| vs SMA50 | Below (USD 24.38) |
| MACD | -1.46 (negative) |
Analyst Ratings (GHRS)
Wall Street analysts rate GHRS "Buy" based on 10 analysts, with a mean price target of USD 42.89 (range USD 38–65), per Nexqual as of October 29, 2026 at 12:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 42.89 |
| High Target | USD 65 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (GHRS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.23 vs est -0.3 ▲ beat |
| 2026-03-31 | USD -0.31 vs est -0.26 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.23 vs est -0.23 ▼ miss |
Source: Nexqual, October 29, 2026 at 12:56 UTC.
Financials & Fundamentals (GHRS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -18.79% |
| Debt / Equity | 0 |
| Current Ratio | 28.7 |
| Total Cash | $362.65M |
| Total Debt | $360,000 |
Source: Nexqual, October 29, 2026 at 12:56 UTC.
Financial Health Score (GHRS)
Nexqual rates GH Research PLC's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 12:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $363M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$52M (TTM) |
| Efficiency | Critical — ROE -19%, ROA -13.0% |
Ownership (GHRS)
| Insider Ownership | +24.46% |
|---|---|
| Institutional Ownership | +72.15% |
| Shares Outstanding | 68.64M |
| Float | 32.37M |
| Short % of Float | +7.47% |
Source: Nexqual, October 29, 2026 at 12:56 UTC.
Leadership (GHRS)
GH Research PLC is led by Velichka Valcheva M.D., M.Sc., Chief Executive Officer, per Nexqual as of October 29, 2026 at 12:56 UTC.
| Chief Executive Officer | Velichka Valcheva M.D., M.Sc. |
|---|---|
| Co-Founder & Non-Executive Chairman of the Board | Florian Schonharting M.Sc. (Econ) |
| Vice President of Finance | Julie Ryan F.C.A. |
| Chief Operating Officer | Aaron Cameron |
Major Backers & Investors (GHRS)
Notable institutional backers of GH Research PLC include Lynx1 Capital Management Lp, BVF Inc., RA Capital Management, L.P., according to Nexqual as of October 29, 2026 at 12:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 19.33% |
| BVF Inc. | 12.61% |
| RA Capital Management, L.P. | 11.13% |
| FMR, LLC | 8.71% |
| RTW Investments LP | 8.65% |
| Deep Track Capital, Lp | 4.86% |
| Fidelity | 4.76% |
| Avoro Capital Advisors LLC | 2.62% |
Source: Nexqual, October 29, 2026 at 12:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 12:56 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt